Matches in DBpedia 2014 for { <http://dbpedia.org/resource/XEN-D0101> ?p ?o. }
Showing items 1 to 13 of
13
with 100 items per page.
- XEN-D0101 abstract "XEN-D0101 is a drug that was developed to treat atrial fibrillation. Xention, a biopharmaceutical company based in Cambridge, United Kingdom, created XEN-D0101 along with other ion channel-modulating drugs. XEN-D0101 is a selective antagonist of the voltage-gated potassium channel Kv1.5. Atrial fibrillation is the main focus of Xention’s drug development, as it is the most common cardiac arrhythmia (irregular heart beat) seen in patients.".
- XEN-D0101 wikiPageID "38855496".
- XEN-D0101 wikiPageRevisionID "548939774".
- XEN-D0101 hasPhotoCollection XEN-D0101.
- XEN-D0101 subject Category:Antiarrhythmic_agents.
- XEN-D0101 subject Category:Potassium_channel_blockers.
- XEN-D0101 comment "XEN-D0101 is a drug that was developed to treat atrial fibrillation. Xention, a biopharmaceutical company based in Cambridge, United Kingdom, created XEN-D0101 along with other ion channel-modulating drugs. XEN-D0101 is a selective antagonist of the voltage-gated potassium channel Kv1.5. Atrial fibrillation is the main focus of Xention’s drug development, as it is the most common cardiac arrhythmia (irregular heart beat) seen in patients.".
- XEN-D0101 label "XEN-D0101".
- XEN-D0101 sameAs m.0ryv_r2.
- XEN-D0101 sameAs Q8041843.
- XEN-D0101 sameAs Q8041843.
- XEN-D0101 wasDerivedFrom XEN-D0101?oldid=548939774.
- XEN-D0101 isPrimaryTopicOf XEN-D0101.